Wedbush restated their outperform rating on shares of Prime Medicine (NYSE:PRME – Free Report) in a report published on Tuesday morning,RTT News reports. They currently have a $13.00 target price on the stock, up from their previous target price of $12.00.
Several other equities research analysts have also issued reports on PRME. Chardan Capital reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Prime Medicine in a research note on Monday, March 3rd. StockNews.com raised Prime Medicine to a “sell” rating in a research note on Tuesday, February 11th. JMP Securities began coverage on Prime Medicine in a research note on Tuesday, December 10th. They issued an “outperform” rating and a $10.00 price objective for the company. Citizens Jmp raised Prime Medicine to a “strong-buy” rating in a research note on Tuesday, December 10th. Finally, Guggenheim reissued a “buy” rating and set a $18.00 price target on shares of Prime Medicine in a research note on Tuesday, December 3rd. One research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Prime Medicine presently has an average rating of “Moderate Buy” and a consensus price target of $13.25.
View Our Latest Analysis on PRME
Prime Medicine Price Performance
Prime Medicine (NYSE:PRME – Get Free Report) last posted its quarterly earnings data on Friday, March 7th. The company reported ($1.65) EPS for the quarter. During the same quarter in the prior year, the firm posted ($2.18) earnings per share. As a group, analysts anticipate that Prime Medicine will post -1.68 earnings per share for the current year.
Institutional Investors Weigh In On Prime Medicine
A number of large investors have recently made changes to their positions in the stock. Chelsea Counsel Co. grew its position in shares of Prime Medicine by 137.4% in the fourth quarter. Chelsea Counsel Co. now owns 186,780 shares of the company’s stock valued at $545,000 after purchasing an additional 108,090 shares in the last quarter. Westwood Holdings Group Inc. grew its position in shares of Prime Medicine by 96.5% in the fourth quarter. Westwood Holdings Group Inc. now owns 883,129 shares of the company’s stock valued at $2,579,000 after purchasing an additional 433,653 shares in the last quarter. Sherbrooke Park Advisers LLC purchased a new stake in shares of Prime Medicine in the fourth quarter valued at approximately $60,000. Point72 Asset Management L.P. purchased a new stake in shares of Prime Medicine in the fourth quarter valued at approximately $200,000. Finally, ProShare Advisors LLC grew its position in shares of Prime Medicine by 24.6% in the fourth quarter. ProShare Advisors LLC now owns 22,186 shares of the company’s stock valued at $65,000 after purchasing an additional 4,375 shares in the last quarter. 70.37% of the stock is currently owned by hedge funds and other institutional investors.
Prime Medicine Company Profile
Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.
See Also
- Five stocks we like better than Prime Medicine
- Retail Stocks Investing, Explained
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- 3 Small Caps With Big Return Potential
- 3 Must-Own Stocks to Build Wealth This Decade
- Quiet Period Expirations Explained
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.